Carmell Therapeutics is a biotechnology company focused on plasma-based bioactive materials.
Here are five things to know:
1. Carmell's technology is based on biologically-active materials manufactured from allogeneic human blood plasma.
2. The company's proprietary process binds and cross-links lyophilized plasma into solid and semi-solid plasma-based materials for orthopedic and surgical site healing applications in a controlled-release/time-release capacity. The company has developed multiple plasma-based bioactive material formulations such as pastes, putties, scaffolds, plugs and screws using pooled plasma from healthy donors.
3. Carmell plans to conduct a phase 3 study of its flagship Bone Healing Accelerant product to seek regulatory approval for use in long bone fractures.
4. Future products will leverage Carmell's technology for gastrointestinal leak sealing, dermatology and more applications.
5. Randy Hubbell serves as Carmell Therapeutics' president and CEO. Mr. Hubbell has 20 years of medical device industry experience.